Eli Lilly Licenses Non-Opioid Pain Drug from Confo Therapeutics
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 8 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2768 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Adding to its pain portfolio, Eli Lilly has entered into a global licensing agreement with Confo Therapeutics for the latter’s lead asset, CFTX-1554, a Phase I oral inhibitor of the angiotensin II type 2 receptor for the treatment of neuropathic pain...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS